Experimental vaccine targets Hard-to-Treat cancers in first human test
NCT ID NCT05964361
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tested a new type of vaccine made from a patient's own immune cells (dendritic cells) that are engineered to target a protein called WT1 found in many cancers. Ten people with advanced esophageal, pancreatic, ovarian, or liver cancer received six vaccines over 12 weeks. The main goals were to see if the vaccine could be made and given safely, and to check for any side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- IL15/IL15Ra/WT1 dendritic cell vaccine
- What this could lead to
- If this vaccine proves safe and effective, it could offer a new treatment option for people with advanced solid tumors that have not responded to standard therapies.
- What could go wrong
- This is a very early, small trial (10 participants) focused on safety and feasibility, not on proving the vaccine works. The vaccine may not shrink tumors or improve survival.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Antwerp University Hospital
Edegem, 2650, Belgium
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Could a vaccine help fight Hard-to-Treat cancers?
- A high-tech camera may take the guesswork out of spotting a dangerous surgery complication
- Blood test score may flag High-Risk esophageal surgery patients
- Can a new PET tracer light up hidden cancers?
- A Two-for-One surgery: could tube removal during Weight-Loss surgery slash ovarian cancer risk?